59 results about "Immunoglobulin domain" patented technology

Design and production of immunoglobulin Fc domains including variants to stabilize their monomeric forms are provided.

A method is provided for separating a protein from one or more other proteins using hydroxyapatite chromatography in which the protein does not bind to hydroxyapatite but the other protein(s) does. In some embodiments, a second protein affixed to a solid support has been used previously to purify the protein by affinity chromatography, and small amounts of the second protein are introduced in the sample during this process. The protein being purified can comprise at least one constant antibody immunoglobulin domain. The second protein can bind to proteins comprising such a domain.

Disclosed are fusion proteins comprising a biologically active molecule and an immunoglobulin (Ig) Fc domain which is linked to the biologically active molecule. The Fc domain is a hybrid human Fc domain of (i) IgG1, IgG2 or IgG4 or (ii) IgG4 and IgD. The hybrid Fc is useful as a carrier of biologically active molecules.

The invention related to intracellular single domain immunoglobulins, and to a method for determining the ability of an immunoglobulin single domain to bind to a target in an intracellular environment, comprising the steps of: a) providing a first molecule and a second molecule, wherein stable interaction of the first and second molecules leads to the generation of a signal; b) providing a single intracellular immunoglobulin domain which is associated with the first molecule, said single immunoglobulin domain being free of complementary immunoglobulin domains; c) providing an intracellular target which is associated with the second molecule, such that association of the immunoglobulin domain and the target leads to stable interaction of the first and second molecules and generation of the signal; and d) assessing the intracellular interaction between the immunoglobulin domain and the target by monitoring the signal.

The present invention relates to a multivalent antibody comprising multiple heavy chain variable regions of antibody linked to each other via a linker comprising an amino acid sequence encoding an immunoglobulin domain or a fragment thereof.

The present invention relates to novel methods for making fusion proteins comprising a cytokine or growth factor fused to an immunoglobulin domain. The growth factor/cytokine can be fused directly to an immunoglobulin domain or through a peptide linker. The purified growth factor/cytokine-IgG fusion proteins produced by the novel methods are biologically active and can be used to treat diseases for which the non-fused growth factor/cytokine are useful.

The present invention relates to single chain polypeptides comprising one or more immunoglobulin Fc domains. In particular the present invention relates to single-chain Fc polypeptides in which at least one functional Fc domain is formed within the polypeptide chain.

The invention relates to the field of antibodies, and particularly to modified antibodies, methods of preparing modified antibodies and uses thereof. More particularly, the invention relates to the preparation of more active IgG antibodies by the addition of an extra immunoglobulin domain to the constant region.

Immunoglobulins which each have one or more amino acid modifications in at least one structural loop region of such immunoglobulins, where the modified loop region specifically binds to an epitope of an antigen to which an unmodified immunoglobulin does not significantly bind, obtained from display libraries.

The present invention is directed to bi-specific monovalent diabodies that comprise an immunoglobulin Fc Domain (“bi-specific monovalent Fc diabodies”) and are composed of three polypeptide chains and which possess at least one binding site specific for an epitope of CD32B and one binding site specific for an epitope of CD79b (i.e., a “CD32B×CD79b bi-specific monovalent Fc diabody”). The bi-specific monovalent Fc diabodies of the present invention are capable of simultaneous binding to CD32B and CD79b. The invention is directed to such compositions, to pharmaceutical compositions that contain such bi-specific monovalent Fc diabodies and to methods for their use in the treatment of inflammatory diseases or conditions, and in particular, systemic lupus erythematosus (SLE) and graft vs. host disease.

The invention concerns the field of recombinant gene engineering. It concerns novel introns and compositions comprising such introns as well as a method to improve expression of polypeptides from nucleic acids such as cloned genes with heterologous introns, especially genes encoding antibodies and antibody derived fragments, and the production of various polypeptides in eukaryotic host cells using said novel intron sequences as heterologous introns.

The present invention provides a single domain antibody (sdAb) scaffold comprising one or more than one non-canonical disulfide bond in the framework region (FR). The one or more than one non-canonical disulfide bond may be formed between cysteines introduced by mutations in FR2 and FR3. In the case where the sdAb scaffold is a V_H, the Cys may be introduced at any one of positions (47-49) and any one of positions (67-71), based on Kabat numbering; in one example, the Cys may be introduced at positions (49) and (69), based on Kabat numbering. In the case where the sdAb scaffold is a V_L, the Cys residues may be introduced at any one of positions 46-49 and any one of positions (62-66), based on Kabat numbering; in one example, the Cys residues may be introduced at positions (48 and 64), based on Kabat numbering.

The invention belongs to the biotechnology field, discloses fusion protein of a prostate specific antigen (PSA) and G-type immunoglobulin domain (IgG Fc), and also discloses a PSA detection kit containing the fusion protein as the standard sample. The invention carries out the fusion expression of the IgG Fc and the PSA, therefore, not only a large amount of fusion protein can be obtained, but also the purification of the fusion protein is very simple, and the bioactivity of the fusion protein is closer to that of the natural PSA. The invention overcomes the technical defects of the difficult recombinant expression and the recombined PSA closer to the natural PSA in the prior art, and greatly reduces the manufacturing cost of the PSA detection kit.

The invention discloses a mouse anti-human TIM3 (T cell immunoglobulin domain and mucin domain protein 3) monoclonal antibody. The mouse anti-human TIM3 monoclonal antibody is stable in performance, high in potency and capable of particularly recognizing expression of TIM3 on surfaces of immune cells and tumor cells. The invention further relates to application of the mouse anti-human TIM3 monoclonal antibody in preparation of an immunohistochemical TIM3 detecting tool. An immunohistochemical method is used to detect the TIM3 for the first time, and scientific references are provided for clinical diagnosis and treatment of non-small cell lung cancer, renal cell carcinoma, hepatocellular carcinoma, melanoma, colon cancer, esophageal cancer and other tumors as well as septicopyemia, systemiclupus erythematosus or related infections and autoimmune diseases. The monoclonal antibody generated from different hybridomas is discovered for the first time can recognize different states of TIM3of a same antigen, by the aid of the discovery, the TIM3 monoclonal antibodies can be screened purposefully, and basic medical research value is realized.

Disclosed are RAGE fusion proteins comprising RAGE polypeptide sequences linked to a second, non-RAGE polypeptide. The RAGE fusion protein may utilize a RAGE polypeptide domain comprising a RAGE ligand binding site and an interdomain linker directly linked to an immunoglobulin CH2 domain. Such fusion proteins may provide specific, high affinity binding to RAGE ligands. Also disclosed is the use of the RAGE fusion proteins as therapeutics for RAGE-mediated pathologies.

Isolated polypeptides comprising a mutant programmed cell death 1 (PD-1) polypeptide and fusion polypeptides comprising an isolated mutant PD-1 polypeptide fused to an immunoglobulin domain polypeptide are provided. Further provided are methods of using a composition comprising the fusion polypeptide for stimulating T cell activation for treating disorders including a tumor or an infection.